

Reviewer 1:

Dr. Hong and colleagues have presented an interesting study in which they aimed to investigate the expression and clinical significance in terms of HCC-development of B7-H4 in dependency of HBx in cell culture and HBV-positive patient samples. The colleagues found that B7-H4 up-regulation in HBx-positive samples were correlated with hepato-carcinogenesis in cell culture and patients. The authors conclude that B7-H4 may be involved in facilitating HBV-related HCC-development. Overall, the manuscript is well written and concise in its content and the methodical design is well performed. However, there are some comments which should be addressed.

- 1) There are some minor spelling and typing errors which should be polished, e.g., in the Abstract, Conclusion first sentence it should read “was” correlated instead of “were”.

Response: We have corrected those errors. And the revision was proofread by a native English professional with science background at Elixigen Corporation.

- 2) Abstract section, Results; the correct abbreviation for the hepatoma cell line is HepG2.2.15

Response: We have corrected the name of hepatoma cell line, using HepG2.2.15 instead of HepG2215.

- 3) Material and Methods, Cell lines; the HepG2.2.15 cells are stably HBV-expressing hepatoma cells derived from HepG2 cells and were firstly described by Sells et al 1987 and 1988 (PNAS 84:1005-1009 and J Virol 62:2836-2844).

Response: We have increased this description of HepG2.2.15 in Material and Methods, Cell lines.

- 4) The Introduction section is informative but much too long and reads like a review article. Please shorten it and focus on the essentials.

Response: We have shortened the introduction and focus on the essentials.

- 5) Table 1 and 2. There are some cryptic signs for Tumor grade and TNM stage. This might be due

to the word file; however, I can't read it.

Response: We have added the description in Page 10. Tumor grade I is well-differentiated and in a low-grade; tumor grade II is medium-differentiated and in a moderate malignant; tumor grade III is poor-differentiated and in a highly malignant. TNM stage refers to the Tumor Node Metastasis stage.

6) Fig. 1a; In my opinion and as a suggestion the density data should be presented as a graph rather than a table.

Response: We have presented the density data as a graph rather instead of a table.

7) Fig. 1 legend; the last sentence of the figure legend is incomplete **, vs HepG2 cells should read HepG2.2.15 vs HepG2

Response: We have completed the figure legend with HepG2.2.15 vs HepG2.

8) Fig.2; it is hard to identify the intracellular localisation of B7-H4 due to the minor quality of the figures. Please enhance the quality of the figures by, e.g., enhancing the magnification.

Response: We have presented figures with higher magnification showing clearly B7-H4 and HBx expression and staining.

9) Fig. 3. The staining of HBx and also B7-H4 is not really convincing. Please present figures with higher magnification showing clearly B7-H4 and HBx expression and staining.

Response: We have presented figures with higher magnification showing clearly B7-H4 and HBx expression and staining.

10) There are two recent reports on B7-H1 expression showing that HBeAg suppresses the cellular immunity by Han et al (Cell Immunol 2013 283:25-30) and especially of Xu et al (Clin Immunol 2010

136:30-41) showing that B7-H4 expression attenuates con-A induced hepatic injury. These reports could be discussed in the context of the findings of the authors.

Response: We have discussed those reports on Page 14.

Substantial research has been performed regarding the role of B7-H4 in tumor immunity. However, the pathophysiologic function of B7-H4 has yet to be fully elucidated. In the present study, we suggested a detrimental role for B7-H4 in HBV-HCC patients. Costimulatory molecules including VCAM-1 [37], CD40 [38], CD28, and PD-1 [39], as well as several members of the B7 superfamily, including B7-1, B7-2 [40], B7-H1 [12,33], and B7-H3 [41] have been reportedly expressed in HCC tissues. These costimulatory molecules could provide positive (VCAM-1, CD28, B7-1, B7-2, and CD40) or negative (PD-1 and B7-H1) signals to local T cells that determine an optimal T cell response and regulate the pathogenesis of HCC. It is reported that HBeAg suppresses the specific cellular immunity which was to clear the virus through up-regulating B7-H1 expression, and eventually lead to immune tolerance to HBV infection [42]. B7-H4 was originally described to be a membrane costimulatory ligand of the B7 superfamily, which is involved in the down-regulation of T cell activation under certain circumstances. Ectopic B7-H4-Ig may protect animals from liver injury induced by ConA, which could be associated with reduced serum levels for IL-2, IFN-gamma and IL-4 as well as enhanced IL-10 production [43]. Thus, B7-H4 may lead to immune tolerance to HBV infection, and play an important role in immune suppression in chronic HBV-HCC patients.

Reviewer 2:

The authors reported that the elevated expression of B7-H2, known as a co-stimulatory molecule, was detected not only HepG2.215 cell lines (transfected with HBV DNA) but also HBV-related hepatocellular carcinoma clinical tissues in this manuscript. Although they showed a positive correlation between HBx and B7-H4 expression in hepatocellular carcinoma of HBV positive patients,

they provide a mere phenomenon. They did not show a role of B7-H4 in this manuscript. Even though they showed a role of B7-H4 in pancreatic carcinoma cells through their previous study, we would like to urge roles of B7-H4 in hepatic cancel cell. For instance, During B7-H4 suppression with its siRNA in HepG2.215 cells, roles of B7-H4 including cell to cell interaction, cell growth, and apoptosis are examined.

Response: We suspected that intracellular B7-H4 might possess an anti-apoptotic effect in HCC cells. We will next determine if this is the function of B7-H4 in this context with future research. We will detect the roles of B7-H4 on cell to cell interaction, cell growth, and apoptosis in HBV-HCC cells by B7-H4 specific shRNA. And we will identify if there is an epitope change of B7-H4 which might be involved in immune-mediated tumor escape, and thereby contributing to tumor development.